Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TXNRD1 | Q16881 | 6/20 | 0.50 |
| ▸ | TXNRD3 | Q86VQ6 | 6/20 | 0.50 |
| ▸ | TXNRD2 | Q9NNW7 | 6/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betadex SCHEMBL193191 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL306328 | 0.99 | ALDH1A1 (0.51) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL21629653 | 0.92 | ALDH1A1 (0.47) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL23198883 | 0.89 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL29414129 | 0.88 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL23198880 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL25413932 | 0.78 | ALDH1A1 (0.80) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Alfadex SCHEMBL25414284 | 0.78 | ALDH1A1 (0.80) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL8746198 | 0.76 | ALDH1A1 (0.83) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Betadex SCHEMBL6516572 | 0.75 | ALDH1A1 (0.80) | ALDH1A1TSHRLMNATDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118319894-A | Pharmaceutical composition and application thereof | 广州润尔眼科生物科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| EP-3548091-A1 | PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY | Oculis SA (CH) | 2019-10-09 | — | — | EP | claimed |
| WO-2018100434-A1 | PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY | OCULIS EHF (IS) | 2018-06-07 | — | — | WO | claimed |
| EP-2854531-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | Verrow Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | claimed |
| US-20140377185-A9 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | VERROW PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | claimed |
| WO-2013180777-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | VERROW PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | WO | claimed |
| US-20130323181-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | VERROW PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | claimed |
| WO-2011088503-A1 | ANAESTHETIC FORMULATION | GOODCHILD INVESTMENTS PTY LTD (AU) | 2011-07-28 | — | — | WO | claimed |
| US-20220096664-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | VERROW PHARMACEUTICALS, INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3548091-A1 | PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY | Oculis SA (CH) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018100434-A1 | PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY | OCULIS EHF (IS) | 2018-06-07 | — | — | WO | disclosed |
| EP-2854531-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | Verrow Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20140377185-A9 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | VERROW PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| CN-102596178-B | Liposomes having an internal aqueous phase of sulfobutyl ether cyclodextrin salt | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUAN | 2014-12-03 | — | — | CN | disclosed |
| WO-2013180777-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | VERROW PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20130323181-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | VERROW PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| CN-102596178-A | Liposomes having an internal aqueous phase of sulfobutyl ether cyclodextrin salt | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2012-07-18 | — | — | CN | disclosed |
| US-8192721-B2 | Compositions useful for reducing toxicity associated with gadolinium-based contrast agents | VERROW PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2011088503-A1 | ANAESTHETIC FORMULATION | GOODCHILD INVESTMENTS PTY LTD (AU) | 2011-07-28 | — | — | WO | disclosed |
| US-20090155181-A1 | Compositions Useful for Reducing Toxicity Associated with Gadolinium-based Contrast Agents | VERROW PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377185-A9 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | ARRB1, GPR119, DSC1 | ALDH1A1 4184/4885TSHR 534/4885LMNA 2021/4885 |
| US-20220096664-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | ARRB1, GPR119, DSC1 | ALDH1A1 4184/4885TSHR 534/4885LMNA 2021/4885 |
| US-20130323181-A1 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS | ARRB1, GPR119, DSC1 | ALDH1A1 4184/4885TSHR 534/4885LMNA 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.